Last reviewed · How we verify
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
Details
| Lead sponsor | Taiho Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 53 |
| Start date | 2007-10 |
| Completion | 2010-03 |
Conditions
- Colorectal Cancer
Interventions
- S-1, Irinotecan, Bevacizumab
Primary outcomes
- Safety — any time
Countries
Japan